Search

Your search for "RENB" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Featured Guest in Recent Proactive Interview

November 22, 2023

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, was featured in a recent Proactive interview. Mark Dybul, CEO of Renovaro, joined host Steve Darling to talk about the company and its achievements and potential. Specifically, the two talked about the company’s […]

InvestorNewsBreaks

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Poised to Spearhead Advancements in Battle Against Diseases, Harness Cutting-Edge AI Technology

November 21, 2023

Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy, recently announced a definitive agreement to combine with the advanced AI company GEDiCube International Ltd, rebranding as Renovaro AI. “The company has also announced the addition of three new members to its board of directors – Avram Miller, Leni Boeren and […]

InvestorNewsBreaks

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Opportunity in Largely Untapped Precision Medicine Market

November 17, 2023

Renovaro BioSciences (NASDAQ: RENB), an advanced, preclinical biotechnology company, and GEDi Cube Intl Ltd., an AI medical technology company, previously announced a definitive agreement to combine. The move brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early detection, diagnostic insights and targeted immunotherapies. “According to CEO Dr. Mark Dybul, […]

News Articles

Renovaro Biosciences Inc. (NASDAQ: RENB) CEO Provides Update on Combination with AI Expert GEDiCube Intl Ltd. in Letter to Shareholders

November 10, 2023

In September, Renovaro Biosciences (NASDAQ: RENB), an advanced, preclinical biotechnology company focused on cell, gene, and immunotherapy, and GEDiCube Intl Ltd., an AI medical technology company, announced a definitive agreement for combination. Under the stock-for-stock agreement, GEDiCube will become a wholly-owned subsidiary of Renovaro. The company’s CEO, Dr. Mark Dybul, MD, recently sent a letter […]

InvestorNewsBreaks

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB), GEDi Cube Combine to Transform Medicine Through AI and Biotherapeutics

November 8, 2023

Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell and immunotherapy platforms that modulate immune responses against cancers and infectious disease, and GEDi Cube International Ltd., an AI medical technology company, recently entered a definitive agreement to combine in a stock-for-stock acquisition. “The combined company will feature two […]

News Articles

Renovaro Biosciences Inc. (NASDAQ: RENB) Announces Three New Members to Board of Directors as Definitive Agreement with GEDiCube Announced

November 6, 2023

Renovaro Biosciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid tumors with short life expectancy, recently announced a definitive agreement to combine with the advanced AI Company GEDiCube Intl Ltd., rebranding as Renovaro AI. The company has also announced the addition of three new members to its board […]

News Articles

Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Provides Insights on Definitive Agreement to Combine with GEDi Cube to Transform Medicine

October 23, 2023

Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell, and immunotherapy platforms that modulate immune responses against cancers and infectious diseases, and GEDi Cube International Ltd., an AI medical technology company, recently signed a definitive agreement to combine in a stock-for-stock acquisition (https://ibn.fm/gA9cq). The combined company brings together […]

InvestorNewsBreaks

InvestorNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Participating in Webinar Focused on Future Health Tech

October 20, 2023

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, will be spotlighted in webinar taking place today. The webinar is scheduled to start at 3 p.m. ET. Renovaro BioSciences CEO Mark Dybul will be featured in the webinar, which […]

InvestorNewsBreaks

InvestorNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Appoints Intel Capital Cofounder to Board

October 11, 2023

Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced a new member of its board of directors. Avram Miller, cofounder of Intel Capital, will join the board and will also serve in an advisory role, bringing his invaluable experience to contribute to the company’s strategy and business development efforts. Miller’s […]

InvestorNewsBreaks

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Strategic Board Appointments of Two Finance Industry Experts

October 10, 2023

Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, today announced the appointment of Leni Boeren and Ruud Hendriks as independent directors. Both Boeren and Hendriks bring extensive, high-level experience in finance and business. Boeren has a 40-year career in the financial […]

InvestorNewsBreaks

InvestorNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Releases Shareholder Letter Regarding Agreement to Combine with Leading AI Company

October 2, 2023

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, is sharing a shareholder letter from Renovaro CEO Mark R. Dybul, MD. In the letter, Dybul provides information about the definitive agreement the company recently signed with artificial intelligence company […]

InvestorNewsBreaks

InvestorNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Enters Definitive Agreement to Combine with Leading AI Tech GEDi Cube

September 29, 2023

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has inked a deal with GEDi Cube Intl Ltd. The agreement is to combine the two companies with GEDi Cube becoming a wholly owned subsidiary of Renovaro in a […]

InvestorNewsBreaks

InvestorNewsBreaks – IBN’s BioMedWire Highlights NanoVibronix Inc.’s (NASDAQ: NAOV) $5M Private Placement

September 21, 2023

IBN, a multifaceted financial news and publishing company for private and public entities, has announced, through its biotech and biomed brand BioMedWire, the recent private placement offering for NanoVibronix (NASDAQ: NAOV), a medical device company that produces the UroShield(R), PainShield(R) and WoundShield(R) Surface Acoustic Wave (“SAW”) Portable Ultrasonic Therapeutic Devices. NanoVibronix in late August entered […]

News Articles

Renovaro BioSciences Inc. (NASDAQ: RENB) Targets Pancreatic Cancer Solution Through Work With GEDI Cube AI Platform, NVIDIA Resources

September 20, 2023

Pre-clinical biotechnology innovator Renovaro BioSciences (NASDAQ: RENB) is seeking solutions for hard-to-treat cancers and other illnesses through the use of a proprietary cell and gene solution designed to promote immune system response. The company has demonstrated the potential of its novel technology against solid tumors in humanized mouse models that demonstrated significant pancreatic tumor size […]

InvestorNewsBreaks

InvestorNewsBreaks – Why Renovaro BioSciences Inc. (NASDAQ: RENB) Is ‘One to Watch’

September 15, 2023

Renovaro BioSciences (NASDAQ: RENB), (formerly Enochian BioSciences Inc.), is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy. “Renovaro aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, as well as to potentially treat or cure serious infectious diseases… The oncology platform is now at the forefront of […]

InvestorNewsBreaks

InvestorNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Congratulates GEDiCube on New Joint Effort Clinical Trials

August 30, 2023

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, released a statement congratulating GEDiCube on its joint effort to accelerate early diagnosis of cancer in clinical trials. GEDiCube is partnering with NVIDIA Inception on clinical trials focused on advancing a unique platform […]

News Articles

Renovaro BioSciences Inc. (NASDAQ: RENB) Aims to Unlock Potential Treatments and Cures for Serious Infectious Diseases and Cancer

August 25, 2023

As an advanced, pre-clinical biotechnology company specializing in cell, gene, and immunotherapy, Renovaro BioSciences (NASDAQ: RENB), formerly Enochian BioSciences Inc., aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (“HIV”) and Hepatitis B Virus (“HBV”) […]

InvestorNewsBreaks

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Clear Path to IND Submission for Innovative Cancer Platform

August 23, 2023

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), announced that it remains confident in submitting an Investigational New Drug Application (“IND”) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the U.S. Food and Drug Administration (“FDA”) on the company’s Pre-IND submission. The company’s proprietary, novel technology uses cell- and gene-therapy […]

News Articles

Renovaro BioSciences Inc. (NASDAQ: RENB), Immunotherapy Biotech Company, Announces Intention to Unite With AI Tech Developer GEDi Cube, Seen as Major Multiplier Effect in the Fight Against Cancer

August 23, 2023

The announcement of a binding and exclusive letter of intent to merge, between two of the most innovative companies in their respective fields, is seen as representing a potentially transformative step in the fight against cancer. Considering Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy, that has already demonstrated […]

InvestorNewsBreaks

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Congratulates GEDi Cube on Appointment of Expert in Clinical Medicine and Digital Health

August 21, 2023

Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy, on Aug. 9 announced an exclusive, binding letter of intent with GEDi Cube. Today Renovaro BioSciences congratulated GEDi Cube on its appointment of Dr. Lester Russell as its chief medical officer. “We are excited about the appointment of Dr. Russell,” said […]

InvestorNewsBreaks

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Discusses Substantial Scientific, Product Development Advances in Letter to Shareholders

August 18, 2023

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), earlier this year issued a letter to shareholders from its CEO Mark Dybul, MD, in which Dr. Dybul discussed scientific and product development advances and plans for the future. The advances included independently conducted studies that showed remarkably promising results, demonstrating and confirming proof-of-concept for the company’s cell-gene-immunotherapy […]

InvestorNewsBreaks

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Presentation of ‘Impressive’ Results from Proof-of-Concept Studies

August 17, 2023

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), in March of 2023 announced that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer, presented proof-of-concept data from two sets of humanized mouse studies conducted independently by her laboratory at the University of California, Los Angeles (“UCLA”). According to the announcement, the […]

InvestorNewsBreaks

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Bright Future in Advancing Potentially Curative Therapies

August 16, 2023

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), is focused on advancing treatments for some of the world’s deadliest diseases. In late 2022, the company announced the award of a U.S. patent for its oncology platform, as well as promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. Scientists at the […]

InvestorNewsBreaks

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Committed to Rapid Advancement of Its Proprietary Oncology Platform

August 15, 2023

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), in late 2022, was awarded a U.S. patent for its proprietary cancer treatment platform that could potentially be used to induce life-long remission from some of the world’s deadliest solid tumors. “We are incredibly excited to have been awarded this patent for Enochian’s allogeneic cell and gene therapy […]

News Articles

Renovaro BioSciences Inc. (NASDAQ: RENB) Is ‘One to Watch’

August 14, 2023

Renovaro BioSciences (NASDAQ: RENB) formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as […]

InvestorNewsBreaks

InvestorNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB), GEDi Cube Announce LOI to Merge, Focus on Fight Against Cancer

August 9, 2023

Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, and GEDi Cube Intl Ltd. have executed a binding, exclusive letter of intent (“LOI”). The LOI outlines the merge of […]

News Articles

Cepton, Inc. (NASDAQ: CPTN) Updates the Market on South African Joint Venture, Reveals Attendance at Investor Conferences

March 16, 2022

Cepton recently revealed that it had recently entered a partnership with Fibre Based Integrations to develop a lidar-based vehicle detection solution, with the goal of furthering Cape Town’s smart transportation infrastructure The smart transportation solution ranks amongst one of over 100 projects which Cepton is currently pursuing, for applications of its lidar technology outside of […]

InvestorNewsBreaks

InvestorNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Secures $25M in Growth Capital, Announces Upcoming Investor Conference Schedule

February 28, 2022

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high performance MMT(R) lidar solutions, has secured a $25 million facility from Trinity Capital Inc. (NASDAQ: TRIN), a leading specialty lending company that provides debt, including loans and equipment financing, to growth-stage companies backed by technology banks, venture capital and private equity firms. The transaction […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).